利妥昔单抗联合贝利尤单抗治疗难治性系统性红斑狼疮合并血栓性微血管病的疗效

doi:10.3969/j.issn.1671-7171.2025.10.028

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1174 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of rituximab combined with belimumab in the treatment of refractory systemic lupus erythematosus (SLE) complicated with thrombotic microangiopathy (TMA). 【Methods】 A total of 80 patients with refractory SLE and TMA were randomly divided into the rituximab monotherapy group (the control group, 37 cases) and the rituximab combined with belimumab group (the combination group, 43 cases). Both groups received treatment for 12 weeks. The therapeutic efficacy, changes in SLE Disease Activity Index (SLEDAI), hematological parameters [white blood cell count (WBC), platelet count (PLT)], renal function indicators [serum creatinine (SCr), urinary red blood cells], immune function markers [complement components 3(C3) and complement components 4(C4)], inflammatory markers [erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP)], and adverse reactions were compared between the two groups before and after treatment. 【Results】 After treatment, the total effective rate in the combination group was 93.02%, significantly higher than 72.97% in the control group (P<0.05). Compared with baseline, both groups showed improvement in all clinical parameters after treatment (P<0.05), with the combination group showing more significant improvements in SLEDAI, WBC, PLT, albumin levels, C3, ESR, and hs-CRP compared with the control group (P<0.05). No significant differences were observed between the two groups in urinary protein, SCr, and urinary red blood cell counts (P>0.05). The incidence of adverse reactions did not differ significantly between groups (P>0.05). 【Conclusion】 Rituximab combined with belimumab in patients with refractory SLE complicated with TMA significantly improves clinical efficacy, hematological and renal function parameters, while maintaining good safety.

Key words： Lupus Erythematosus, Systemic Thrombotic Microangiopathies Rituximab

Received: 10 April 2025

PACS:

R593.241

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Lijuan
	HAN Lishuai

Cite this article:

ZHANG Lijuan,HAN Lishuai. Efficacy of Rituximab Combined with Belimumab in the Treatment of Refractory Systemic Lupus Erythematosus Complicated with Thrombotic Microangiopathy[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(10): 1777-1780.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.10.028 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I10/1777

[1] KIRKPATRICK K V, NOCTON J J. Unusual presentations of systemic lupus erythematosus[J].Med Clin North Am,2024, 108(1): 43-57.
[2] VEGA G,TORSTEN W.What is proven in the treatment of systemic lupus erythematosus?[J].Inn Med (Heidelb),2023,64(12):1135-1142.
[3] MOHAMMAD A,CYNTHIA M,SURYA S, et al.Deposition of complement components C5b-9 and MASP2 in tissues is not a feature of GVHD and may assist in discriminating GVHD from thrombotic microangiopathy following allogenic transplantation[J].Bone Marrow Transplant,2023,58(11):1270-1274.
[4] 陈丽珍,陈红.他克莫司联合利妥昔单抗治疗系统性红斑狼疮的临床疗效研究[J].中国现代药物应用,2024,18(9):23-27.
[5] 吴东明,艾克达,蒋昱,等. 贝利尤单抗联合标准方案治疗活动性狼疮肾炎的疗效及安全性分析[J].中华肾脏病杂志,2023,39(4):245-252.
[6] FAEGHEH C E,ASGHAR A E,FAROOGH K F, et al.Association of IL-17 serum levels with clinical findings and systemic lupus erythematosus disease activity index[J].Immunol Med,2023,46(4):175-181.
[7] RACHEL T,NIDHI P,KARDIE T, et al.Atherosclerosis in systemic lupus erythematosus[J].Curr Atheroscler Rep,2023,25(11):819-827.
[8] FRANCESCO V,LISI P A,CARMEN C, et al.Caveolin-1 in situ expression in glomerular and peritubular capillaries as a marker of ultrastructural progression and severity of renal thrombotic microangiopathy[J].J Nephrol,2023,36(8):2327-2333.
[9] YOUNGWOO J.Identifying and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing[J].Korean J Intern Med,2023,38(6):785-786.
[10] 徐甜,施璇,谢筱彤,等. 贝利尤单抗在一例活动性狼疮肾炎年轻女性患者中的应用[J].中华肾脏病杂志,2021,37(4):366-368.
[11] 王豪,吴芳,徐如芹,等. 利妥昔单抗治疗难治性系统性红斑狼疮继发抗磷脂综合征伴Libman-Sacks 1例[J].中华风湿病学杂志,2023,27(5):327-330.
[12] 檀晓华,李彩凤,赵文甲,等. 贝利尤单抗治疗儿童难治性系统性红斑狼疮15例的疗效及预后随访研究[J].中华实用儿科临床杂志,2022,37(13):983-987.
[13] PANKTI M,YURI A G,OLENA Z, et al.Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management[J].Clin Rheumatol,2022,41(9):2893-2910.
[14] 朱桂芝,王峰,曲燕,等. 系统性红斑狼疮患者血小板参数及血小板反应蛋白1水平与疾病活动度的关系[J].医学临床研究,2024,41(2):258-261.
[15] 周芳,张琼. 系统性红斑狼疮患者血清miRNA-182的表达变化及其临床意义[J].医学临床研究,2023,40(5):738-740.